Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2010 February;51(1) > The Journal of Cardiovascular Surgery 2010 February;51(1):115-19

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE JOURNAL OF CARDIOVASCULAR SURGERY

A Journal on Cardiac, Vascular and Thoracic Surgery


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632


eTOC

 

REVIEWS  THE FUTURE OF SFA TREATMENT: NEW TECHNOLOGIES


The Journal of Cardiovascular Surgery 2010 February;51(1):115-19

language: English

Are drug-eluting stents the future of SFA treatment?

Bosiers M. 1, Deloose K. 1, Keirse K. 2, Verbist J. 2, Peeters P. 2

1 Department of Vascular Surgery, AZ St-Blasius, Dendermonde, Belgium;
2 Department of Cardiovascular & Thoracic Surgery, Imelda Hospital, Bonheiden, Belgium


FULL TEXT  


Drug-eluting stent (DES) technology was developed to prevent early thrombosis and late luminal loss to potentially improve long-term patency rates. Although favorable DES results have recently become available with the Zilver® PTX™ and STRIDES studies, the high price of DES is a major drawback for this technology to become the golden standard for peripheral endovascular therapy in de novo femoro-popliteal (FP) lesions. Nevertheless, DES has the potential to make the difference and to establish itself as an important treatment option in patients presenting with TASC C&D FP lesions who are at high-risk for surgery and for the treatment of in-stent restenosis, where until now, no valuable treatment option has proven to be beneficial.

top of page

Publication History

Cite this article as

Corresponding author e-mail

marc.bosiers@telenet.be